ALK and non-small cell lung carcinoma: The China Food and Drug Administration (CFDA) granted full approval for crizotinib in the treatment of patients with ALK‐positive NSCLC on January 22, 2013 and Ventana IHC (D5F3) has been approved by the CFDA as an aid in identifying patients who are eligible for treatment with crizotinib.31